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BACKGROUND: Varenicline may be associated with
greater mood disturbance and side-effects among
smokers with psychiatric history, but empirical evi-
dence is limited. Differential treatment effectiveness by
psychiatric history may also exist.
OBJECTIVE: To compare mood, prevalence and inten-
sity of treatment side-effects, and abstinence among
people with a probable history of major depression (DH+)
ornot (DH−) who took vareniclineand receivedbehavioral
smoking cessation treatment.
DESIGN: Smokers participated in a randomized behav-
ioral intervention effectiveness trial. Treatment side-
effects and outcomes were compared between DH+ and
DH− participants (n=1,117) at 2 days and 3 months
after the target quit date.
PARTICIPANTS: Smokers recruited from a large region-
al health plan.
MEASUREMENTS: Change in stress and depression
scores, prevalence and intensity of treatment side-
effects, and abstinence rates.
RESULTS: All side-effects averaged moderate intensity
or less and were similar across DH groups, except DH+’s
endorsed slightly worse confusion, nausea (adjusted
P=0.04) and trouble sleeping (adjusted P=0.008) at
21 days. Depression and stress scores declined in both
DH groups and an equal proportion of each evidenced
new/worsening depressive symptoms. Despite few differ-
ences in symptom intensity, more DH+ participants
reported recent tension/agitation, irritability/anger, con-
fusion, and depression at 21 days (adjusted P<0.05),and
depression and anxiety (adjusted P<0.01) at three
months. Nonsmoking rates did not differ by DH group at
follow-up.
CONCLUSION: While some group differences were
noted, DH+ smokers did not report qualitatively worse
neuropsychiatric symptoms, more new/worsening
mood disturbance, or differential abstinence rates
compared to DH- smokers.
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INTRODUCTION
Varenicline (AKA Chantix®) is the latest smoking cessation
medication approved by the U.S. Food and Drug Administration
(FDA). It significantly increases abstinence rates compared to
placebo, bupropion, and NRT
1–7. However, post-marketing sur-
veillance and case reports have raised concerns about potential
adverse effects associated with this medication while quitting
smoking
8–13. Based on reports to the FDA, varenicline use may
increase neuropsychiatric symptoms such as depressed mood,
agitation, and suicidalideationand behavior, particularlyamong
persons with a psychiatric history. At this time, however, it is not
clear if smokers with psychiatric history are, in fact, at greater
risk for these disturbances compared to smokers with no prior
psychiatric history. Individuals with psychiatric diagnoses were
excluded from the initial efficacy trials and, to date, only one
published trial has offered varenicline to persons with self-
reported mental illness
14. This study found no greater medica-
tion side-effects or differential cessation outcomes among
smokerswithmentalillnesscomparedtopersons withnohistory
of mental illness, but the psychiatric sample was small (n=55)
and included people with varying clinical diagnoses. A recent
case series of smokers with stable schizophrenia also found no
evidence of worsening mood or psychosis during varenicline
treatment
15, but again the sample was small (n=19) and
psychotic symptoms were not monitored with standardized
measures. At present, more empirical data are needed to
determine if persons with psychiatric history experience worse
outcomes or side-effects when using varenicline, and if so,
whether certain psychiatric groups are at greater risk than
others. In the meantime, the FDA warns consumers to inform
their providers of any prior psychiatric conditions before starting
varenicline and to immediately report any changes in mood or
behavior after beginning treatment
8.
The current paper examines mood, other self-reported
symptoms commonly associated with varenicline use and/or
nicotine withdrawal, and abstinence following varenicline
initiation among smokers with and without a probable lifetime
history of depression. In clinical cessation trials, as many as
35% to 60% of smokers have a positive depression history
16–19,
and in a large epidemiological sample, 39% of smokers with
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563moderate nicotine dependence had major depression
20. Thus,
depression is prevalent among smokers. Smokers with a
history of depression are also more likely to suffer recurrent
major depression after quitting
21, have higher relapse and
lower quit rates
22–24, and report more severe nicotine with-
drawal symptoms
25. Based on these findings and the FDA
warnings, we expected persons with a likely history of depres-
sion (DH+) would report worse treatment side-effects and lower
abstinence rates than persons with no apparent history of
depression (DH−). However, varenicline, α4β2 partial agonist,
may also help attenuate negative affect and improve outcomes
as it is thought to both block nicotine uptake and stimulate the
dopaminergic reward pathway. A recent study found vareni-
cline reduced negative affect and improved positive affect
during active treatment compared to placebo
26. Persons with
and without psychiatric history were not compared, so it is
unclear if this effect would vary based on depression history.
However, if varenicline improves mood among DH+ smokers,
differences in treatment outcomes between DH+ and DH−
smokers may not be as pronounced as in prior trials.
Data were collected as part of the COMPASS study, a
randomized clinical smoking cessation trial. The purpose of
COMPASS was to compare the effectiveness of three behavioral
programs for smoking cessation, all offered with varenicline.
Given the current warnings about varenicline use among
smokers with prior psychiatric history, we report changes in
mood which would indicate new or worsening depression post-
medication exposure, as well as differences in a range of side-
effects commonly associated with varenicline use and/or
nicotine withdrawal. These include neuropsychiatric symptoms
highlighted in the FDA warnings and other symptoms which
might suggest DH+ have a qualitatively worse treatment experi-
ence. We are not able to discern which reported symptoms are
due to medication use versus nicotine withdrawal, both because
there is an overlap in the side-effects attributed to each and due
to our study design, but we are able to comment on the overall
subjective symptom experience reported by DH+ and DH−
smokers and the observed abstinence rates among DH group
participants treated with varenicline.
METHODS
Setting, Recruitment, and Intervention Procedures
COMPASS was conducted by Group Health (GH), SRI Interna-
tional (SRI), and Free & Clear, Inc. (F&C). GH is a large not-for-
profit regional U.S. health plan. SRI is a non-profit independent
research organization, and F&C is the U.S.’s largest vendor of
tobacco quitline services.
Smokers (n=1,202) were recruited from GH and randomized
to one of three behavioral treatment programs (phone-based
counseling, web-based intervention, or combined phone and
web-based intervention). Participants also received varenicline
and were instructed to begin taking it one week prior to their
target quit date (set at treatment initiation) and follow stan-
dard dosing instructions for three months. Additional details
on the intervention are described elsewhere
27,28.
All study activities were approved by the appropriate
Institutional Review Boards (IRBs). Study enrollment began
in October 2006 and completed in October 2007.
Participants
Individuals were eligible if they met the following criteria: were
18 years or older; smoked ≥ 10 cigarettes per day over the past
year and ≥ 5 cigarettes per day over the past week; were ready
to quit smoking; could read and speak English; had telephone
and Internet access; and were enrolled in Group Health.
All study-related treatment was delivered remotely with no
in-person provider contact. Consequently, our IRBs advised
more stringent exclusion criteria than recommended at the
time for varenicline. The following were our exclusion criteria:
current/planned pregnancy or breast feeding; self-report of
poor health, severe heart disease or COPD; on dialysis or with
certain kidney disease; self-reported current diagnosis or
treatment of schizophrenia, bipolar disorder, or mania; high
frequency alcohol use over the past six months (> two drinks
per day almost every day) and/or binge drinking two or more
times in the last month; current use of other cessation
treatment; current use of investigational or recreational/street
drugs or cimetidine, metformin, phenformin, pindolol or
procainamide (drugs thought to potentially interfere with renal
clearance of varenicline)
29.
Assessment
Enrolled participants were interviewed by phone at baseline,
21 days post-target quit date, and three months’ post-target
quit date. Baseline assessment included participant demo-
graphics, smoking history, nicotine dependence assessed via
the Fagerström Test of Nicotine Dependence (FTND)
30, per-
ceived stress (a measure of subjective distress)
31, depression
history and current depressive symptoms. Depression history
was assessed using an item reflecting the two hallmark
symptoms of major depression in the Diagnostic and Statisti-
cal Manual of Mental Disorders IV
32. Participants were asked
to indicate if they had ever in their lifetime experienced a
period of two weeks or more when they felt down, depressed or
hopeless or had little interest or pleasure in doing things (yes/
no). A “yes” was considered indicative of probable lifetime
major depression (DH+) and a “no” indicative of no apparent
major depression history (DH−). Current depressive symptoms
were assessed using a brief measure derived from the Hopkins
Symptom Checklist
33. This measure evaluates depressive
symptoms (disturbed sleep, low energy, blaming self, feeling
blue, feeling everything is an effort, hopelessness about the
future). Respondents rated how much they were bothered by
each symptom in the past month on a 4-point scale ranging
from ‘not at all’ to ‘extremely.’ Mean score was calculated. Both
the depression history and depressive symptom screens
were previously found to be inversely predictive of smoking
cessation
19,34.
At follow-up, participants reported their current smoking
status, varenicline use, current depressive symptoms, and
side-effects during the past month. Side-effects included
symptoms associated with varenicline based on the original
clinical trials and prescribing information (e.g., nausea, vomit-
ing, change in appetite) and symptoms commonly associated
with quitting smoking and nicotine withdrawal (e.g., irritabil-
ity, depression, anxiety, desire to smoke)
35–38.F o re a c h
symptom endorsed in the prior month, participants rated the
severity on a 5-point Likert scale ranging from ‘very mild’ to
‘very severe.’ Non-smoking was defined as a self-report of not
564 McClure et al.: Mood, Side-effects and Smoking Outcomes Among Persons Taking Varenicline JGIMsmoking, even a puff, for the last seven days (point prevalent
abstinence).
Data Analyses
Descriptive results are reported for enrolled participants who
provided depression history status at baseline (n=1,117).
Analyses of side-effects and mood were limited to members of
the respondent samples at each follow-up who had taken
varenicline prior to assessment, regardless of dose or duration.
Smoking outcomes were examined using conventional intent-
to-treat (ITT) analyses where missing participants were
counted as smokers (n=1,117) and using a respondent only
sample.
Depression history group differences were examined using
chi-square analyses for categorical variables and t-tests for
continuous variables. Because we were interested in the
change in depression and perceived stress over time, change
in each scale score from baseline to follow-up was computed.
Logistic regression models were run for unadjusted and
adjusted analyses of binary responses (e.g., smoking outcome)
and generalized linear models were run for unadjusted and
adjusted analyses of continuous variables (e.g. depression and
perceived stress scale scores, and change in these scale scores
from baseline).
RESULTS
Participants
Participant characteristics at baseline are presented in Table 1.
Over half (56.2%) endorsed symptoms suggestive of lifetime
major depression (DH+). These individuals were more likely to
be older, female, white, and unmarried. DH− participants were
more likely to have started taking varenicline by 21 days, but
groups were equally likely to have taken the medication by
three months and equally likely to participate in each follow-
up. An equal proportion of serious adverse events were
reported by both DH groups.
Medication Use
All participants had taken varenicline prior to each follow-up,
but were not necessarily taking varenicline at the time of
assessment. A comparison of DH groups on medication usage
showed that equal proportions were taking varenicline at
21 days (83.7% DH+ vs. 82.4% DH−, P=0.59) and three
months (35.2% DH+ vs. 38.4% DH−, P=0.34). However, DH+
participants were more likely to report intentionally taking
fewer pills in a day than prescribed at 21 days (16.8% vs.
11.9%, P=0.03), but not at three months (27.0% DH+ vs.
27.9% DH−, P=0.77). Reports of taking more varenicline in a
day than prescribed were very low (less than 2%) and did not
differ between groups at either follow-up.
Change in Depressive Symptoms and Perceived
Stress
Mean depression and perceived stress scores were higher
among DH+ participants at baseline (P<0.001) and declined
among both DH groups over time (see Figs. 1 and 2). Since
groups differed on several baseline covariates, we examined
mean change from baseline to each follow-up controlling for
the baseline value of each measure plus gender, marital status
(married/not married) age, race (white, not white), and behav-
ioral treatment group. Adjusted mean change in depression
score was greater for the DH− group at 21 days (−0.19 DH+ vs.
−0.33 DH−, P<0.001) and three months (−0.22 DH+ vs. −0.32
DH−, P=0.02). Reductions in adjusted mean change from
baseline were greater for DH− participants’ perceived stress
scores at 21 days (−0.31 DH+ vs. −0.92 DH−, P<0.001), but not
at three months (−0.68 DH− vs. −0.42 DH+, P=0.19).
We also examined the proportion of each DH group whose
depressive symptom scores worsened from baseline to follow-
up. Symptoms were considered significantly worse if scores
went from below the cut-point suggestive of clinically mean-
ingful symptomology (mean = 0.75)
39 at baseline to above it at
either follow-up. At 21 days, depressive symptom scores
significantly increased in 9.7% of DH+ and 7.9% of DH−’s( P=
0.33). At three months, 12.0% of DH+ and 10.3% of DH−’s
depression scores worsened compared to their score at 21 days
(P=0.44), and 8.9% of DH+ and 7.6% of DH−’s scores were
worse compared to baseline (P=0.48).
Table 1. Characteristics of Participants with and without a Probable
History of Depression
Probable Depression
History *
DH+ DH−
Characteristic (n=661) (n=516) P
Age, years (M, SD) 48.1 (11.0) 46.2 (10.8) 0.004
Gender (% female) 75.2 56.8 <0.001
Race (% white) 91.9 86.9 0.006
Marital status (% married) 59.1 70.3 <0.001
Years of formal schooling
(M, SD)
14.1 (2.2) 13.9 (2.2) 0.10
Cigarettes per day at baseline
(M, SD)
19.6 (8.0) 19.8 (8.3) 0.72
FTND (M, SD) 5.0 (2.0) 4.9 (2.3) 0.58
Treatment group 0.04
Phone counseling program (%) 35.7 30.6 –
Internet program (%) 34.2 32.4 –
Phone + Internet program (%) 30.1 37.0 –
Completed 21 day interview
(%, n yes)
85.6 (566) 83.1 (429) 0.24
Took medication by 21 day
interview (% yes)
†
95.8 98.1 0.04
Completed 3 month interview
(%, n yes)
75.9 (502) 75.8 (391) 0.95
Took medication by 3 month
interview (% yes)
†
98.2 98.7 0.54
Reported a serious adverse event
during study (%)
0.76 0.78 0.97
*DH+ participants indicated a probable history of prior major depression
at baseline. DH – participants denied symptoms suggestive of a probable
lifetime major depression episode
†Respondent sample at each follow-up. Proportions reflect the percentage
of people who completed the follow-up interview and had taken
varenicline, regardless of dose or duration
‡Proportion of DH groups who reported a serious adverse event (SAE)
requiring medical treatment during the study period (6 months). DH+
SAE’s (n=5) included chest pain, allergic reaction, heart attack/MI,
collapsed lung, and depression with suicidal ideation. DH− SAE’s( n = 4 )
included nausea with vomiting, hospitalization (unknown cause), and
two cardiac-related deaths
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After controlling for baseline differences, DH+ participants
were more likely to report tension/agitation, irritability/anger,
depression, difficulty concentrating, and confusion at 21 days
(see Table 2). At three months, groups differed only with
respect to the proportion reporting anxiety (37.0% DH+ vs.
21.3% DH−, OR=1.68 [1.21–2.34]. P=0.002) and depression
(31.9% DH+ vs. 15.9% DH−, OR=1.90 [1.32−2.71], P<0.001)
in adjusted analyses.
The severity of each symptom endorsed was also examined.
None of the severity ratings averaged more than moderate
intensity for either DH group. In adjusted analyses, DH+
participants endorsed more severe difficulty sleeping (P=
0.008), nausea (P=0.04) and confusion (P=0.04), but groups
were otherwise similar. At three months, there were no group
differences in any severity ratings after controlling for baseline
differences (data not shown).
Mean severity ratings can obscure the occurrence of more
severe symptom cases. Thus, the number and proportion of
people who endorsed each symptom and rated it as severe or
very severe was also examined (Table 3). More DH+ partici-
pants rated their depression as severe/very severe (adjusted
P=0.02) at 21 days. No other differences were observed at
either follow-up after controlling for baseline differences (data
not shown).
Smoking Status
There was no difference in ITT non-smoking rates between DH
groups at 21 days (48.6% DH+ vs. 47.3% DH−; OR=1.05, 95%
CI=0.84–1.33, P=0.66) or three months (44.8% DH+ vs.
41.98% DH−; OR=1.13, 95% CI=0.89–1.42, P=0.32). These
findings remained after controlling for relevant baseline cov-
ariates, including gender, age, marital status, race, FTND
score, baseline depressive symptom score, and behavioral
treatment group at 21 days (OR=1.18, 95% CI=0.91–1.52,
P=0.21) and three-month follow-up (OR 1.20, 95% CI=0.92–
1.55, P=0.17). Results were similar in the respondent only
analyses (DH+ 56.7% vs. DH− 56.9%, OR=0.99, 95% CI=0.77–
1.28, P=0.96 at 21 days, n=995; DH+ 59.1% vs. DH− 55.4%,
OR=1.16, 95% CI=0.89–1.52, P=0.27 at three months, n=
891). These findings also remained after controlling for the
baseline covariates above at 21 days (OR=1.09, 95% CI=0.82–
1.45, P=0.53, n=919) and three months (OR=1.26, 95% CI=
0.93–1.70; P=0.22, n=823).
COMMENT
Empirical data are needed to examine whether smokers with
and without psychiatric history at treatment onset experience
differential mood disturbance, side-effects or abstinence rates
after taking varenicline. In this trial, smokers with a probable
lifetime history of depression (DH+) were more likely to report a
number of neuropsychiatric side-effects after initiating vareni-
cline treatment including tension/agitation, irritability/anger,
depression, difficulty concentrating, and confusion; however,
the data do not indicate these individuals were more likely to
experience new or significantly worse mood disturbance
compared to DH− participants, particularly after baseline
differences were taken into account. Depression and perceived
stress scores declined in both groups over time. Subjective
side-effect symptom ratings averaged moderately intense or
less for both groups across all monitored side-effects and were
similarly intense between DH groups except for nausea, sleep
disturbance, and confusion assessed early in the treatment
period (21 days post-target quit date). Each of these symptoms
was rated as slightly worse among DH+ participants, but
indices of mood were not different. Finally, a similar proportion
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Figure 2. Change in perceived stress score from baseline to follow-
up*. *Scores reflect unadjusted means with 95% confidence
intervals indicated for each data point. Adjusted mean change
from baseline to each follow-up is presented in the text and was
significantly greater for DH- participants at each follow-up.
† DH+
participants indicated a probable history of prior major depression
at baseline. DH – participants denied symptoms suggestive of a
probable lifetime major depression episode.
‡ Perceived stress
scores range from 0 to 16 and reflect symptoms over the past
month. Higher scores indicate greater perceived stress, a subjec-
tive measure of distress.
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Figure 1. Change in depression score from baseline to follow-up*.
*Scores reflect unadjusted means, with 95% confidence intervals
indicated for each data point. Adjusted mean change from
baseline to each follow-up is presented in the text and was
significantly greater for DH– participants at each follow-up.
† DH+
participants indicated a probable history of prior major depression
at baseline. DH – participants denied symptoms suggestive of a
probable lifetime major depression episode.
‡ Depression symp-
tom scores range from 0 to 4 and reflect symptoms over the past
month. Higher scores indicate greater depression.
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follow-up indicative of a potentially clinically meaningful
decline in mood. And while more DH+ participants rated their
recent depression as ‘severe’ or ‘very severe,’ this affected only
24 out of 542 participants in this group. Differences in
abstinence rates were also not observed. In fact, non-smoking
rates for both DH groups were similar to those observed in the
clinical efficacy trials
1,2. One explanation for these findings
Table 2. Proportion of Varenicline Users Reporting Symptoms at 21-Day Follow-up by Depression History Group
Probable Depression
History *
Unadjusted Regression Adjusted Regression
†
% DH+ % DH−
Symptom
‡ (n=542) (n=421) P OR (95% CI)
‖ P
§ OR (95% CI)
‖
Nausea
¶ 61.6 53.3 0.01 1.40 (1.08–1.81) 0.13 1.24 (0.94–1.65)
Retching
¶ 11.7 7.6 0.04 1.60 (1.02–2.50) 0.17 1.39 (0.86–2.23)
Vomiting
¶ 12.0 7.4 0.02 1.72 (1.10–2.69) 0.12 1.47 (0.91–2.36)
Gas
¶ 57.8 53.0 0.14 1.22 (0.94–1.57) 0.57 1.08 (0.82–1.43)
Dysgeusia
¶ 49.5 43.7 0.08 1.26 (0.98–1.64) 0.22 1.19 (0.90–1.56)
Change in appetite
¶# 49.0 46.7 0.48 1.10 (0.85–1.42) 0.96 0.99 (0.75–1.31)
Change in dreaming
¶ 58.0 56.0 0.53 1.09 (0.84–1.41) 0.57 1.08 (0.82–1.43)
Difficulty sleeping
¶ 46.4 39.3 0.03 1.34 (1.03–1.73) 0.50 1.10 (0.83–1.46)
Constipation
¶# 34.1 30.0 0.17 1.21 (0.92–1.59) 0.50 1.11 (0.82–1.49)
Desire to smoke
# 80.3 75.7 0.09 1.31 (0.96–1.78) 0.31 1.19 (0.85–1.65)
Tension/agitation
# 51.0 39.7 <0.001 1.58 (1.22–2.05) 0.02 1.39 (1.05–1.83)
Irritability/anger
¶# 47.1 36.3 <0.001 1.57 (1.21–2.03) 0.009 1.46 (1.10–1.93)
Anxiety
¶# 38.6 27.9 <0.001 1.62 (1.23–2.14) 0.08 1.30 (0.97–1.75)
Depression
¶# 28.9 15.1 <0.001 2.29 (1.65–3.17) <0.001 1.81 (1.28–2.58)
Difficulty concentrating
# 33.4 22.5 <0.001 1.73 (1.29–2.31) 0.005 1.57 (1.15–2.15)
Confusion
¶ 19.3 8.6 <0.001 2.54 (1.70–3.80) <0.001 2.16 (1.41–3.32)
*DH+ participants indicated a probable history of prior major depression at baseline. DH – participants denied symptoms suggestive of a probable lifetime
major depression episode
†Adjusted for treatment group, gender, age, married, white, depression scale score at baseline
‡Reflects symptoms experienced in the past month at each follow-up
§P = p-value for DH term in logistic regression
‖ OR = odds ratio; CI = confidence interval
¶ Symptom commonly associated with varenicline use
# Symptom commonly associated with nicotine withdrawal
Table 3. Varenicline Users Rating Each Symptom as Severe or Very Severe among Symptom Endorsers
21-Day Follow-up 3-Month Follow-up
Probable Depression
History *
Probable Depression
History *
DH+ DH− Unadj Adj.
‡ DH+ DH− Unadj Adj
‡
Symptom % (N)
† %( N)
† PP%( N)
† %( N)
† PP
Nausea
¶ 23.2 (77) 18.3 (41) 0.17 0.29 17.9 (34) 20.2 (24) 0.62 0.96
Retching
¶ 30.2 (19) 18.8 (6) 0.23 0.30 22.2 (10) 13.8 (4) 0.37 0.58
Vomiting
¶ 26.2 (17) 22.6 (7) 0.71 0.66 27.5 (11) 15.4 (4) 0.26 0.31
Gas
¶ 20.3 (63) 19.9 (44) 0.92 0.58 18.6 (44) 10.1 (18) 0.02 0.16
Dysgeusia
¶ 13.6 (36) 19.3 (35) 0.11 0.20 14.4 (28) 13.0 (18) 0.71 0.95
Change in appetite
¶# 12.9 (34) 16.9 (33) 0.23 0.33 16.5 (28) 18.5 (25) 0.64 0.49
Change in dreaming
¶ 33.7 (104) 31.8 (74) 0.64 0.93 27.3 (53) 27.1 (36) 0.96 0.92
Difficulty sleeping
¶ 25.0 (62) 18.9 (31) 0.15 0.20 20.5 (44) 16.3 (23) 0.33 0.77
Constipation
¶# 22.3 (41) 14.4(18) 0.08 0.13 15.5 (23) 11.4 (10) 0.37 0.23
Desire to smoke
# 18.1 (78) 17.8 (56) 0.93 0.60 22.7 (87) 26.8 (71) 0.23 0.16
Tension/agitation
# 8.4 (23) 7.2 (12) 0.67 0.53 7.2 (15) 6.9 (9) 0.91 0.86
Irritability/anger
¶# 12.4 (31) 19.2 (29) 0.06 0.08 11.2 (21) 11.3 (15) 0.99 0.33
Anxiety
¶# 12.0 (25) 10.3 (12) 0.63 0.92 9.9 (18) 9.8 (8) 0.97 0.87
Depression
¶# 15.4 (24) 3.2 (2) 0.01 0.02 8.9 (14) 6.6 (4) 0.57 0.60
Difficulty concentrating
# 8.9 (16) 7.4 (7) 0.68 0.71 12.4 (17) 8.1 (6) 0.34 0.73
Confusion
¶ 3.8 (4) 2.8 (1) 0.77 0.49 7.9 (6) 2.5 (1) 0.25 0.29
*DH+ participants indicated a probable history of prior major depression at baseline. DH – participants denied symptoms suggestive of a probable lifetime
major depression episode
†Percent of people who rated each symptom as ‘severe’ or ‘very severe’ over the past month among those who endorsed each symptom. N = the number
who rated each symptom as ‘severe’ or ‘very severe’
‡Adjusted for treatment group, gender, age, married, white, depression scale score at baseline
¶Symptom thought to be associated with varenicline use
# Symptom thought to be associated with nicotine withdrawal
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nicotine cravings varenicline, an α4β2 partial agonist, may curb
post-quitting negative affect and, in turn, enhance quit rates.
If these findings are replicated, it could suggest varenicline
is an appealing treatment option for some DH+ smokers.
However, more research is needed. Data from this study alone
are not enough to conclude that varenicline is equally safe and
effective in psychiatric and non-psychiatric samples. A num-
ber of limitations prevent this. First, the study did not include
a no-medication control group. This was not necessary for the
aims of the behavioral intervention trial, but would be required
to determine whether each of the observed symptoms were due
to varenicline, nicotine withdrawal, or other factors. Next, we
cannot absolutely conclude whether participants met diagnos-
tic criteria for current or past major depressive disorder. The
proportion of people with a probable history of major depres-
sion (56%) is consistent with results from other smoking
cessation trials (35% to 60%)
16–19, but it is possible that
lifetime depression was over-identified with our brief screen-
ing. This screen, however, is consistent with the assessment a
clinician might use in a brief clinical encounter. As such,
determining if smokers identified with this methodology are at
greater risk of adverse events is clinically relevant. Next, the
timing of the assessments does not allow comment on whether
side-effects were exacerbated after people stopped taking
varenicline, as has been suggested by some
9,40. However, most
side-effect differences observed were at 21 days. At this
assessment point, 82–83% of respondents were still taking
varenicline. By the three-month follow-up, only about a third
of each group was still taking varenicline, and there were no
differences in symptom severity ratings, so it seems unlikely
that medication discontinuance drove the disparities observed
in this study. Finally, the data do not allow us to comment on
potential interactions between varenicline use and other
psychiatric conditions.
This study also has several notable strengths. COMPASS is
the first completed smoking cessation effectiveness trial to use
varenicline post-FDA approval. Although the study design has
limitations, it is also the best empirical data currently available
to examine disparities in side-effects or outcomes by DH group.
It was conducted in a real-world setting, exclusion criteria were
less restrictive than in the original efficacy trials, persons with
major depression were included in the sample, and all outcomes
were systematically monitored at each follow-up.
CONCLUSIONS
Additional research is needed to more fully evaluate vareni-
cline safety, particularly among smokers with active or prior
psychiatric history. Until then, clinicians should carefully
monitor patients on this drug. Data from this study suggest
smokers with a likely history of depression are more likely to
report common side effects associated with varenicline and/or
nicotine withdrawal, but worsening mood, qualitatively worse
overall side-effects, and differential smoking outcomes were
not observed between depression history groups in this study.
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